STAAR Surgical (STAA)

Medical lens company STAAR Surgical (NASDAQ:STAA) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 18.1% year on year to $57.8 million. Its GAAP loss of $0.37 per share was significantly below analysts’ consensus estimates.

Company Overview

With over 2.5 million implants performed worldwide, STAAR Surgical (NASDAQ:STAA) designs and manufactures implantable lenses that correct vision problems without removing the eye's natural lens.

The medical devices industry operates a business model that balances steady demand with significant investments in innovation and regulatory compliance. The industry benefits from recurring revenue streams tied to consumables, maintenance services, and incremental upgrades to the latest technologies, although specialty devices are more niche. The capital-intensive nature of product development, coupled with lengthy regulatory pathways and the need for clinical validation, can weigh on profitability and timelines. In addition, there are constant pricing pressures from healthcare systems and insurers maximizing cost efficiency. Over the next several years, one tailwind is demographic–aging populations means rising chronic disease rates that drive greater demand for medical interventions and monitoring solutions. Advances in digital health, such as remote patient monitoring and smart devices, are also expected to unlock new demand by shortening upgrade cycles. On the other hand, the industry faces headwinds from pricing and reimbursement pressures as healthcare providers increasingly adopt value-based care models. Additionally, the integration of cybersecurity for connected devices adds further risk and complexity for device manufacturers.

STAAR Surgical's main competitors in the ophthalmic medical device market include Alcon (NYSE:ALC), Johnson & Johnson Vision (NYSE:JNJ), Bausch Health Companies (NYSE:BHC), and Carl Zeiss Meditec AG (ETR:AFX).

Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.

With just $239.4 million in revenue over the past 12 months, STAAR Surgical is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive.

A company’s long-term sales performance is one signal of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Luckily, STAAR Surgical’s sales grew at a decent 7.9% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. STAAR Surgical’s recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 13.8% over the last two years.

This quarter, STAAR Surgical’s revenue grew by 18.1% year on year to $57.8 million but fell short of Wall Street’s estimates.

Looking ahead, sell-side analysts expect revenue to grow 31.5% over the next 12 months, an improvement versus the last two years. This projection is eye-popping and implies its newer products and services will fuel better top-line performance.

Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D.

STAAR Surgical was roughly breakeven when averaging the last five years of quarterly operating profits, lousy for a healthcare business.

Analyzing the trend in its profitability, STAAR Surgical’s operating margin decreased by 52.8 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 47 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.

This quarter, STAAR Surgical generated an operating margin profit margin of negative 39.5%, up 17.5 percentage points year on year. This increase was a welcome development and shows it was more efficient.

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Sadly for STAAR Surgical, its EPS declined by 73.2% annually over the last five years while its revenue grew by 7.9%. This tells us the company became less profitable on a per-share basis as it expanded.

Diving into the nuances of STAAR Surgical’s earnings can give us a better understanding of its performance. As we mentioned earlier, STAAR Surgical’s operating margin expanded this quarter but declined by 52.8 percentage points over the last five years. Its share count also grew by 1.9%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders.

In Q4, STAAR Surgical reported EPS of negative $0.37, up from negative $0.69 in the same quarter last year. Despite growing year on year, this print missed analysts’ estimates. Over the next 12 months, Wall Street is optimistic. Analysts forecast STAAR Surgical’s full-year EPS of negative $1.63 will flip to positive $0.09.

Although earnings are undoubtedly valuable for assessing company performance, we believe cash is king because you can’t use accounting profits to pay the bills.

STAAR Surgical broke even from a free cash flow perspective over the last five years, giving the company limited opportunities to return capital to shareholders.

Taking a step back, we can see that STAAR Surgical’s margin dropped by 29.9 percentage points during that time. Almost any movement in the wrong direction is undesirable because of its already low cash conversion. If the trend continues, it could signal it’s in the middle of a big investment cycle.

STAAR Surgical burned through $5.59 million of cash in Q4, equivalent to a negative 9.7% margin. The company’s cash burn was similar to its $5.08 million of lost cash in the same quarter last year.

EPS and free cash flow tell us whether a company was profitable while growing its revenue. But was it capital-efficient? A company’s ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity).

STAAR Surgical historically did a mediocre job investing in profitable growth initiatives. Its five-year average ROIC was 5%, somewhat low compared to the best healthcare companies that consistently pump out 20%+.

We like to invest in businesses with high returns, but the trend in a company’s ROIC is what often surprises the market and moves the stock price. Over the last few years, STAAR Surgical’s ROIC has unfortunately decreased significantly. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.

Companies with more cash than debt have lower bankruptcy risk.

STAAR Surgical is a well-capitalized company with $187.5 million of cash and $38.35 million of debt on its balance sheet. This $149.2 million net cash position is 15.7% of its market cap and gives it the freedom to borrow money, return capital to shareholders, or invest in growth initiatives. Leverage is not an issue here.

We struggled to find many positives in these results. Its revenue missed and its EPS fell short of Wall Street’s estimates. Overall, this quarter could have been better. The stock traded down 10.9% to $16.87 immediately following the results.

The latest quarterly earnings matters, sure, but we actually think longer-term fundamentals and valuation matter more. Investors should consider all these pieces before deciding whether or not to invest in STAAR Surgical.

We cheer for all companies helping people live better, but in the case of STAAR Surgical, we’ll be cheering from the sidelines. Although its revenue growth was decent over the last five years and is expected to accelerate over the next 12 months, its diminishing returns show management's prior bets haven't worked out. On top of that, the company’s declining EPS over the last five years makes it a less attractive asset to the public markets.

STAAR Surgical’s P/E ratio based on the next 12 months is 35.4x. At this valuation, there’s a lot of good news priced in - we think there are better stocks to buy right now.

Wall Street analysts have a consensus one-year price target of $22.73 on the company (compared to the current share price of $16.87).

Although the price target is bullish, readers should exercise caution because analysts tend to be overly optimistic. The firms they work for, often big banks, have relationships with companies that extend into fundraising, M&A advisory, and other rewarding business lines. As a result, they typically hesitate to say bad things for fear they will lose out. We at StockStory do not suffer from such conflicts of interest, so we’ll always tell it like it is.